ReviewCold Spring Harbor perspectives in medicine2019
Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.
Review in Cold Spring Harbor perspectives in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Combined MYC Activation and PTEN Loss Drives Molecular Features of Aggressive Preinvasive Lesions in Mouse Prostate.Molecular cancer research : MCR · 2026Article
- Obesity-linked genes may promote prostate cancer among Asian and Hispanic immigrants to North America.Frontiers in public health · 2026Review
- International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.The American journal of surgical pathology · 2025Article
- International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.The American journal of surgical pathology · 2025Article
- Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies.Histology and histopathology · 2025Review
- The impact of zinc and testosterone co-treatment on tumourigenesis in prostate cancer: a novel model.BMC cancer · 2025Article
- Programmed Cell Death in Cancer.MedComm · 2025Review
- Precision Therapy for Prostate Cancer: Advancements in Polymeric Nanocarrier Systems.Anti-cancer agents in medicinal chemistry · 2025Review
- Defining precancer: a grand challenge for the cancer community.Nature reviews. Cancer · 2024Review
- Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.Nature communications · 2024Article
- Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact.Cancers · 2024Review
- Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate.The Prostate · 2024Article
- MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression.JCI insight · 2023Article
- Preliminary study on miRNA in prostate cancer.World journal of surgical oncology · 2023Article
- Progressive Spreading of DNA Methylation in the GSTP1 Promoter CpG Island across Transitions from Precursors to Invasive Prostate Cancer.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Prostate cancer epidemiology and prognostic factors in the United States.Frontiers in oncology · 2023Article
- Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets.American journal of cancer research · 2021Review
- GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.PloS one · 2021Article
- A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.Nature cancer · 2020Article
- An in Situ Atlas of Mitochondrial DNA in Mammalian Tissues Reveals High Content in Stem and Proliferative Compartments.The American journal of pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
A better understanding of the early stages of prostate cancer initiation, potentially arising from precursor lesions, may fuel development of powerful approaches for prostate cancer prevention or interception. The best-known candidate for such a precursor lesion has been referred to as high-grade prostatic intraepithelial neoplasia (HGPIN). Although there is significant evidence supporting the notion that such HGPIN lesions can give rise to invasive adenocarcinomas of the prostate, there are also numerous complicating considerations and evidence that cloud the picture in many instances. Notably, recent evidence has suggested that some fraction of such lesions that are morphologically consistent with HGPIN may actually be invasive carcinomas masquerading as HGPIN-a state that we term "postinvasive intraepithelial carcinoma" (PIC). Although the prevalence of such PIC lesions is not fully understood, this and other factors can confound the potential of identifying prostate precursors that can be targeted for disease prevention, interception, or treatment. Here, we review our current understanding of the morphological and molecular pathological features of prostate cancer precursor lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.